Special Issue "New Technologies and Theories for Tumor Drug Development"

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 3028

Special Issue Editors

School of Pharmacy, Anhui Medical University, Hefei 230032, China
Interests: tumor metastasis; miRNA detection; fluorescence; photothermal therapy; nanomaterials; tumor resistance
School of Pharmacy, Anhui Medical University, Hefei 230032, China
Interests: targeted delivery systems; nanoparticle delivery systems; traditional Chinese medicines (TCMs)
Department of Pharmaceutical Sciences: Pharmaceutical Chemistry, Faculty of Pharmacy, University of Salamanca, CIETUS, IBSAL, 37007 Salamanca, Spain
Interests: medicinal chemistry; organic synthesis; drug development; natural products; hybridization; antitumoral; immunotherapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In recent years, the development of anti-tumor drugs has ushered in rapid development, with the emergence of new drugs often being accompanied by new theoretical breakthroughs. Attention has been paid to the development trends of anti-tumor drugs. Such drugs include nano targeted materials, small-molecule drugs, immune drugs, and characteristic Chinese herbal medicine. In this Special Issue, entitled “New Technologies and Theories for Tumor Drug Development”, we invite the submission of original research articles or reviews on different aspects of this emerging research field.

Areas of interest include, but are not limited to:

  • Nano targeted materials;
  • Small-molecule drugs and immune drugs;
  • Characteristic Chinese herbal medicine;
  • Mechanisms of tumor metastasis drug intervention.

Dr. Jie Wang
Dr. Jihui Tang
Dr. Angela Patricia Hernandez
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • chemotherapy drugs
  • nano targeted materials
  • immunotherapy
  • mechanisms of tumor metastasis
  • Chinese herbal medicine

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Review
Current Trends in Neoantigen-Based Cancer Vaccines
Pharmaceuticals 2023, 16(3), 392; https://doi.org/10.3390/ph16030392 - 05 Mar 2023
Viewed by 2668
Abstract
Cancer immunotherapies are treatments that use drugs or cells to activate patients’ own immune systems against cancer cells. Among them, cancer vaccines have recently been rapidly developed. Based on tumor-specific antigens referred to as neoantigens, these vaccines can be in various forms such [...] Read more.
Cancer immunotherapies are treatments that use drugs or cells to activate patients’ own immune systems against cancer cells. Among them, cancer vaccines have recently been rapidly developed. Based on tumor-specific antigens referred to as neoantigens, these vaccines can be in various forms such as messenger (m)RNA and synthetic peptides to activate cytotoxic T cells and act with or without dendritic cells. Growing evidence suggests that neoantigen-based cancer vaccines possess a very promising future, yet the processes of immune recognition and activation to relay identification of a neoantigen through the histocompatibility complex (MHC) and T-cell receptor (TCR) remain unclear. Here, we describe features of neoantigens and the biological process of validating neoantigens, along with a discussion of recent progress in the scientific development and clinical applications of neoantigen-based cancer vaccines. Full article
(This article belongs to the Special Issue New Technologies and Theories for Tumor Drug Development)
Show Figures

Figure 1

Back to TopTop